Michel Bourin and Corina Prica Pages 1675 - 1682 ( 8 )
Agomelatine markedly differs from other classes of antidepressant drugs: its primary molecular targets in vivo are the melatonin MT1 and MT2 receptors, where it acts as a potent agonist, and the 5-HT2C receptors, where it exerts clear-cut antagonist properties. Agomelatine across a wide range of clinical trials suggests that agomelatine offers an important alternative for the treatment of depression, combining efficacy, even in the most severely depressed patients, with a favorable side-effect profile. It will be of interest to see if agomelatine expands the spectrum of treatment for unipolar depression. It shows efficacy in acute phase and in of maintenance treatment compared to reference antidepressants as paroxetine and venlafaxine.
Agomelatine,duloxetine,unipolar depression
, Michel Bourin, EA 3256 Neurobiologie de l'anxiete et de la depression, Faculte de Medecine 1, rue Gaston Veil BP 53508 44035 Nantes cedex 01, France.